Fighting fire with fire: Mass antimalarial drug administrations in an era of antimalarial resistance

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 6, 2015, Pages 715-730

  Von Seidlein, Lorenz ^a   Dondorp, Arjen ^b,c  

^a MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

artemisinins; chloroquine; drug resistance; elimination; malaria; mass drug administrations; Plasmodium falciparum; pyrimethamine; sulfadoxine

Indexed keywords

ALBENDAZOLE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; ATOVAQUONE; AZITHROMYCIN; BENFLUMETOL; CHLOROQUINE; CYCLOGUANIL; DIETHYLCARBAMAZINE; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; IVERMECTIN; MEBENDAZOLE; MEFLOQUINE; MEPACRINE; PAMAQUINE; PIPERAQUINE; PRAZIQUANTEL; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; SULFADOXINE;

ANTIMALARIAL DRUG RESISTANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; LOW DRUG DOSE; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MASS DRUG ADMINISTRATION; NONHUMAN; PARASITE TRANSMISSION; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX MALARIA; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG RESISTANCE; HISTORY; MALARIA, FALCIPARUM;

ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SULFADOXINE;

EID: 84929255823     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1031744     Document Type: Review

References (162)

1. New-South-Wales-Rural-Fire-Service. GUIDELINES for Low Intensity Bush Fire Hazard Reduction Burning 2003. Available from: www.hillside.rfsa.org.au/ lowintensityhrburn.pdf
2. Wikipedia. Controlled burn. 2014. Available from: http://en.wikipedia.org/wiki/ Controlled-burn
3. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002;2(4):209-18
4. Peters W. Chemotherapy and drug resistance in malaria. Academic Press; London: 1987
5. Bjorkman A, Phillips-Howard PA. The epidemiology of drug-resistant malaria. Trans R Soc Trop Med Hyg 1990;84(2): 177-80
6. Looareesuwan S, Viravan C, Webster HK, et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996;54(1):62-6
7. White NJ. Qinghaosu (artemisinin): the price of success. Science 2008;320(5874): 330-4
8. Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359(24):2619-20
9. Coatney R. Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg 1963;12:121-8
10. Price RN, von Seidlein L, Valecha N, et al. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 2014; 14(10):982-91
11. Fitch CD, Chevli R, Banyal HS, et al. Lysis of Plasmodium falciparum by ferriprotoporphyrin IX and a chloroquine-ferriprotoporphyrin IX complex. Antimicrob Agents Chemother 1982;21(5):819-22
12. Lehane AM, McDevitt CA, Kirk K, Fidock DA. Degrees of chloroquine resistance in Plasmodium-is the redox system involved? Int J Parasitol Drugs Drug Resist 2012;2:47-57
13. Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000;6(4):861-71
14. Martin RE, Marchetti RV, Cowan AI, et al. Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science 2009;325(5948):1680-2
15. Sanchez CP, McLean JE, Rohrbach P, et al. Evidence for a pfcrt-associated chloroquine efflux system in the human malarial parasite Plasmodium falciparum. Biochemistry 2005; 44(29):9862-70
16. Bray PG, Martin RE, Tilley L, et al. Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol Microbiol 2005;56(2):323-33
17. Fitch CD. Chloroquine resistance in malaria: a deficiency of chloroquine binding. Proc Natl Acad Sci USA 1969; 64(4):1181-7
18. Krogstad DJ, Gluzman IY, Kyle DE, et al. Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science 1987;238(4831):1283-5
19. Saliba KJ, Folb PI, Smith PJ. Role for the plasmodium falciparum digestive vacuole in chloroquine resistance. Biochem Pharmacol 1998;56(3):313-20
20. Sullivan DJ Jr, Gluzman IY, Russell DG, Goldberg DE. On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci USA 1996; 93(21):11865-70
21. Cowman AF, Karcz S, Galatis D, Culvenor JG. A P-glycoprotein homologue of Plasmodium falciparum is localized on the digestive vacuole. J Cell Biol 1991; 113(5):1033-42
22. Wootton J, Feng X, Ferdig M, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002;418:320-3
23. Young MD, Johnson CM. Plasmodium falciparum malaria in Panama resistant to 4-aminoquinoline drugs. Am J Trop Med Hyg 1972;21:13-17
24. Moore DV, Lanier JE. Observations on two Plasmodium falciparum infections with an abnormal response to chloroquine. Am J Trop Med Hyg 1961;10:5-9
25. Box E, Box Q, Young M. Chloroquine-resistant Plasmodium falciparum from Porto Velho, Brazil. Am J Trop Med Hyg 1963;12:300-4
26. Ferraroni JJ, Speer CA, Hayes J, Suzuki M. Prevalence of chloroquine-resistant falciparum malaria in the Brazilian Amazon. Am J Trop Med Hyg 1981;30:526-30
27. Vieira P, Ferreira M, Alecrim M, et al. pfcrt Polymorphism and the spread of chloroquine resistance in Plasmodium falciparum populations across the Amazon Basin. J Infect Dis 2004;190:417-24
28. Juliao PC, Sosa S, Gonzalez LD, et al. Importation of chloroquine-resistant Plasmodium falciparum by Guatemalan peacekeepers returning from the Democratic Republic of the Congo. Malar J 2013;12:344
29. Eyles D, Hoo C, Warren M, Sandosham A. Plasmodium falciparum resistant to chloroqione in Cambodia. Am J Trop Med Hyg 1963;12:840-3
30. Harinasuta T, Suntharasamai P, Viravan C. Chloroquine-resistant falciparum malaria in Thailand. Lancet 1965;2:657-60
31. Li Y. Qinghaosu (artemisinin): chemistry and pharmacology. Acta Pharmacol Sin 2012;33(9):1141-6
32. Croft AM. A lesson learnt: the rise and fall of Lariam and Halfan. J R Soc Med 2007; 100(4):170-4
33. Cai X. Investigation of the sensitivity of Plasmodium falciparum to chloroquine at Quianjia, hainan island. Chin J Prev Med 1982;16:6-9
34. Clyde D, Hlaing N, Tin F. Resistance to chloroquine of Plasmodium falciparum from Burma. Trans R Soc Trop Med Hyg 1972;66:369-70
35. Rosenberg R, Maheswary N. Chloroquine resistant Plasmodium falciparum in Bangladesh. Trans R Soc Trop Med Hyg 1976;70:533
36. Sehgal P, Sharma M, Sharma S, Gogai S. Resistance to chloroquine in falciparum malaria in Assam state, India. J Comm Dis 1973;5:175-80
37. Meuwissen JHET. The antimalaria campaign with medicated salt in Western New Guinea. Thesis. Leyden: 1963
38. Meuwissen JHET. The use of medicated salt in an antimalaria campaign in West New Guinea. Trop Geogr Med 1964;16: 245-55
39. Ebisawa I, Fukuyama T. Chloroquine resistance of Plasmodium falciparum in West Irian and East Kalimantan. Ann Trop Med Parasitol 1975;69:275-82
40. Clyde D, McCarthy V, Miller R, Hornick R. Chloroquine-resistant falciparum malaria from Irian Jaya (Indonesian New Guinea). J Trop Med Hyg 1976;79:38-41
41. Han C, Grimmond T. Chloroquine resistance trials in Papua New Guinea 1. Maprik and Popondetta areas. P N G Med J 1976;19:236-42
42. Pribadi W, Dakung L, Gandahusada S. Daldyono. Chloroquine resistant Plasmodium falciparum infection fromLampung and South Sumatra, Indonesia. Southeast Asian J Trop Med Public Health 1981;12:69-73
43. Mita T, Kaneko A, Hombhanje F, et al. Role of pfmdr1 mutations on chloroquine resistance in Plasmodium falciparum isolates with pfcrt K76T from Papua New Guinea. Acta Trop 2006;98:137-44
44. Mehlotra RK, Mattera G, Bockarie MJ, et al. Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother 2008;52:2212-22
45. Chen N, Wilson D, Pasay C, et al. Origin and dissemination of chloroquine-resistant Plasmodium falciparum with mutant pfcrt alleles in the Philippines. Antimicrob Agents Chemother 2005;49:2102-5
46. Campbell C, Chin W, Collins W, et al. Chloroquine-resistant Plasmodium falciparum from East Africa: cultivation and drug sensitivity of the Tanzanian I/CDC strain from an American tourist. Lancet 1979;2:1151-4
47. Fogh S, Jepsen S, Effersoe P. Chloroquine-resistant Plasmodium falciparum malaria in Kenya. Trans R Soc Trop Med Hyg 1979;73:228-9
48. Mita T, Tanabe K. Evolution of Plasmodium falciparum drug resistance: implications for the development and containment of artemisinin resistance. Jpn J Infect Dis 2012;65(6):465-75
49. Mita T, Tanabe K, Kita K. Spread and evolution of Plasmodium falciparum drug resistance. Parasitol Int 2009;58(3):201-9
50. Attaran A, Barnes KI, Curtis C, et al. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 2004;363(9404):237-40
51. Hastings IM, Korenromp EL, Bloland PB. The anatomy of a malaria disaster: drug policy choice and mortality in African children. Lancet Infect Dis 2007;7(11): 739-48
52. Okungu V, Gilson L. 'still waiting for chloroquine': the challenge of communicating changes in first-line treatment policy for uncomplicated malaria in a remote Kenyan district. Malar J 2014;13:258
53. Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 2001;64(1-2 Suppl):12-17
54. Trape JF, Pison G, Preziosi MP, et al. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III 1998;321(8): 689-97
55. Korenromp EL, Williams BG, Gouws E, et al. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis 2003;3(6):349-58
56. Severini C, Menegon M, Sannella A, et al. Prevalence of pfcrt point mutations and level of chloroquine resistance in Plasmodium falciparum isolates from Africa. Infect Genet Evol 2006;6:262-8
57. Fairley N. Discussion in symposium on pyrimethamine. Trans R Soc Trop Med Hyg 1952;46:508
58. Archibald H. Preliminary field trials on a new schizonticide. Br Med J 1951;2:821-3
59. Harinasuta T, Viravan C, Reid H. Sulphormethoxine in chloroquine resistant falciparum malaria in Thailand. Lancet 1967;1:657-60
60. Silva J, Lopes P. Resistencia do Plasmodium falciparum aos antimalaricos de sintese. Hospital (Rio J) 1966;69:967-79
61. Bzik DJ, Li WB, Horii T, Inselburg J. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci USA 1987;84(23):8360-4
62. Cowman AF, Morry MJ, Biggs BA, et al. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 1988;85(23):9109-13
63. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 1988;85(23):9114-18
64. Sirawaraporn W, Sathitkul T, Sirawaraporn R, et al. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 1997;94(4):1124-9
65. Lozovsky ER, Chookajorn T, Brown KM, et al. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci USA 2009;106(29):12025-30
66. Brown KM, Costanzo MS, Xu W, et al. Compensatory mutations restore fitness during the evolution of dihydrofolate reductase. Mol Biol Evol 2010;27(12): 2682-90
67. Hyde JE. Antifolate resistance in Africa and the 164-dollar question. Trans R Soc Trop Med Hyg 2008;102(4):301-3
68. Triglia T, Cowman AF. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 1994;91(15): 7149-53
69. Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 1997; 94(25):13944-9
70. Triglia T WP, Sims PF, Hyde JE, Cowman AF. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. Embo J 1998;17:3807-15
71. Alam MT, de Souza DK, Vinayak S, et al. Selective sweeps and genetic lineages of Plasmodium falciparum drug-resistant alleles in Ghana. J Infect Dis 2011;203(2): 220-7
72. Alam MT, Vinayak S, Congpuong K, et al. Tracking origins and spread of sulfadoxine-resistant Plasmodium falciparum dhps alleles in Thailand. Antimicrob Agents Chemother 2011;55(1):155-64
73. Vinayak S, Alam MT, Mixson-Hayden T, et al. Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog 2010;6(3):e1000830
74. Roper C, Pearce R, Nair S, et al. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004;305:1124
75. Nair S, Williams J, Brockman A, et al. A selective sweep driven by pyrimethamine treatment in Southeast Asian malaria parasites. Mol Biol Evol 2003;20:1526-36
76. Maiga O, Djimde A, Hubert V, et al. A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa. J Infect Dis 2007;196: 165-72
77. Ali S, Najmi M, Tarning J, Lindegardh N. Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. Malar J 2010;9:275
78. Lefevre G, Bindschedler M, Ezzet F, et al. Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur J Pharm Sci 2000;10:141-51
79. Lefevre G, Looareesuwan S, Treeprasertsuk S, et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001;64:247-56
80. Tarning J, Ashley EA, Lindegardh N, et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 2008;52:1052-61
81. Lwin K, Phyo A, Tarning J, et al. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly ihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 2012;56:1571
82. Ministry-of-Health. The principle and usage of antimalarial drugs in China. Chin J Parasit Dis Con 2002;15:129-30
83. Vugt MV, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999;60(6): 936-42
84. von Seidlein L, Milligan P, Pinder M, et al. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet 2000;355(9201): 352-7
85. Looareesuwan S, Viravan C, Vanijanonta S, et al. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet 1992;339(8797):821-4
86. Nosten F, Luxemburger C, ter Kuile FO, et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 1994;170(4):971-7
87. Hatz C, Abdulla S, Mull R, et al. Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years. Trop Med Int Health 1998;3(6):498-504
88. Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004; 363(9402):9-17
89. Cahill K. Preventive diplomacy: stopping wars before they start. Basic Books, New York; 1996
90. Hartwig CL, Rosenthal AS, D'Angelo J, et al. Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent. Biochem Pharmacol 2009;77(3):322-36
91. Kannan R, Sahal D, Chauhan VS. Heme-artemisinin adducts are crucial mediators of the ability of artemisinin to inhibit heme polymerization. Chem Biol 2002;9(3):321-32
92. Klonis N, Crespo-Ortiz MP, Bottova I, et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci USA 2011;108(28):11405-10
93. Denis MB, Tsuyuoka R, Poravuth Y, et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 2006; 11(9):1360-6
94. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361(5):455-67
95. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014;371(5):411-23
96. Saunders DL, Vanachayangkul P, Lon C, et al. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 2014;371(5): 484-5
97. Thriemer K, Hong NV, Rosanas-Urgell A, et al. Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam. Antimicrob Agents Chemother 2014;58(12):7049-55
98. Tun KM, Imwong M, Lwin KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis 2015. [Epub ahead of print]
99. Ariey F. A molecular marker of artemisinin resistant Plasmodium falciparum malaria. Nature 2014;505:50-5
100. Straimer J. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 2015; 347(6220):428-31
101. Mok S. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 2015;347(6220):431-
102. Vogel G. The genetics of resistant malaria. Science 2014;346:1276-8
103. Taylor S, Parobek C, DeConti D, et al. Absence of putative Plasmodium falciparum artemisinin resistance mutations in sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis 2015; 211(5):680-8
104. Takala-Harrison S, Jacob CG, Arze C, et al. Independent emergence of artemisinin resistance mutations among plasmodium falciparum in Southeast Asia. J Infect Dis 2015;211(5):670-9
105. Miotto O, Amato R, Ashley EA, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet 2015; 47(3):226-34
106. Hotez P. Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases. Clin Pharmacol Ther 2009;85(6):659-64
107. Sergent E, Sergent E. Etudes epidemiologiques et prophylactices du paludisme. Neuvieme et dixieme campagnes en Algerie en 1910 et 1911. Annales Del'Institute Pasteur 1913:373-90
108. Newby G, Hwang J, Koita K, et al. Review of mass drug administration and primaquine use for malaria. 2014; In press
109. Garfield R. Malaria control in Nicaragua: social and political influences on disease transmission and control activities. Lancet 1999;354(9176):414-18
110. Garfield RM, Vermund SH. Changes in malaria incidence after mass drug administration in Nicaragua. Lancet 1983; 2(8348):500-3
111. Garfield RM, Vermund SH. Malaria in Nicaragua: an update. Lancet 1984;1(8386): 1125
112. Joncour G. La lutte contre le paludisme a Madagascar. Bull World Health Organ 1956;15:711-23
113. Han E-T, Lee D-H, Park K-D. Reemerging vivax malaria: changing patterns of annual incidence and control programs in the Republic of Korea. Korean J Parasitol 2006;44:285-94
114. Hsiang M, Hwang J, Tao A. Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China. Malar J 2013;12:383
115. Kaneko A, Taleo G, Kalkoa M, et al. Malaria eradication on islands. Lancet 2000; 356(9241):1560-4
116. Kaneko A, Taleo G, Yaviong J, et al. Eradication of malaria on an island of Vanuatu: persistence of immune response after 7 years. BSP; London: 1999
117. Kaneko A, Taleo GK, Rieckman KH. Island malaria control in eastern Melanasia: 1) Malaria eliminated from a small island by 9-week mass drug administration and impregnated bednets. Jpn J Parasitol 1994; 43(5):358-70
118. Poirot E, Skarbinski J, Sinclair D, et al. Mass drug administration for malaria. Cochrane Database Syst Rev 2013;12: CD008846
119. Payne D. Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? Parasitol Today 1988;4(4):112-15
120. Verdrager J. Epidemiology of emergence and spread of drug-resistant falciparum malaria in Southeast Asia. Southeast Asian J Trop Med Public Health 1986;17(1): 111-18
121. Pinotti M. Chemoprophylaxis of malaria by the association of an antimalarial drug to the sodium chloride used daily in the preparation of meals. In: V Congres internationaux de Medicine tropicale et du Paludisme. Istanbul: 1953. p. 248-58
122. Pinotti M. Um novo metodo de profilaxia da malaria: associacao de uma droga antimalarica ao sal de cozinha usado na alimentacao diaria. Rev Bras Malariol Doencas Trop 1954;6:5-12
123. Pinotti M, Ary GS, Lobo-Damasceno G, Soares R. Field tests of chloroquin-table salt mixture. Rev Bras Malariol Doencas Trop 1955;7(1):5-23
124. Silva R, Paiva CH. The Juscelino Kubitschek government and the Brazilian Malaria Control and Eradication Working Group: collaboration and conflicts in Brazilian and international health agenda, 1958-1961. Hist Cienc Saude Manguinhos 2015;22(1):95-114
125. Verdrager J. Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Southeast Asian J Trop Med Public Health 1995;26(1):23-8
126. Verdrager J. Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. J Trop Med Hyg 1986;89(6):277-89
127. Wegener HC. Antibiotics in animal feed and their role in resistance development. Curr Opin Microbiol 2003;6(5):439-45
128. WHO. Global plan for artemisinin resistance containment (GPARC). WHO; Geneva: 2011
129. WHO-Malaria-Policy-Advisory Committee-and-Secretariat. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. Malar J 2012;11:424
130. Ishengoma DS, Mmbando BP, Segeja MD, et al. Declining burden of malaria over two decades in a rural community of Muheza district, north-eastern Tanzania. Malar J 2013;12:338
131. Trape JF, Tall A, Sokhna C, et al. The rise and fall of malaria in a West African rural community, Dielmo, Senegal, from 1990 to 2012: a 22 year longitudinal study. Lancet Infect Dis 2014;14(6):476-88
132. Masaninga F, Chanda E, Chanda-Kapata P, et al. Review of the malaria epidemiology and trends in Zambia. Asian Pac J Trop Biomed 2013;3(2):89-94
133. Ngomane L, de Jager C. Changes in malaria morbidity and mortality in Mpumalanga Province, South Africa (2001-2009): a retrospective study. Malar J 2012;11:19
134. Maude RJ, Pontavornpinyo W, Saralamba S, et al. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J 2009;8:31
135. David JP, Ismail HM, Chandor-Proust A, Paine MJ. Role of cytochrome P450s in insecticide resistance: impact on the control of mosquito-borne diseases and use of insecticides on Earth. Philos Trans R Soc Lond B Biol Sci 2013;368(1612):20120429
136. Gatton ML, Chitnis N, Churcher T, et al. The importance of mosquito behavioural adaptations to malaria control in Africa. Evolution 2013;67(4):1218-30
137. Nkya TE, Akhouayri I, Kisinza W, David JP. Impact of environment on mosquito response to pyrethroid insecticides: facts, evidences and prospects. Insect Biochem Mol Biol 2013;43(4): 407-16
138. White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet 2014;383(9918): 723-35
139. Imwong M, Hanchana S, Malleret B, et al. High-throughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias. J Clin Microbiol 2014; 52(9):3303-9
140. Halliday E. Impact of intermittent screening and treatment for malaria among school children in Kenya: a cluster randomised trial. PLOS Med 2014;11(1):e1001594
141. Tiono AB, Ouedraogo A, Ogutu B, et al. A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso. Malar J 2013;12:79
142. Cook J, Xu W, Msellem M, et al. Mass screening and treatment on the basis of results of a plasmodium falciparum-specific rapid diagnostic test did not reduce malaria incidence in Zanzibar. J Infect Dis 2014. [Epub ahead of print]
143. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J 2014;13:418
144. Hanboonkunupakarn B, Ashley EA, Jittamala P, et al. Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrob Agents Chemother 2014;58(12):7340-6
145. White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J 2012;11:418
146. Sutanto I, Suprijanto S, Kosasih A, et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial. Clin Infect Dis 2013;56(5):685-93
147. Njomo D, Mukoko D, Nyamongo N, Karanja J. Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One 2014; 9(1):e83413
148. Dial N, Ceesay S, Gosling R, et al. A qualitative study to assess community barriers to malaria mass drug administration trials in The Gambia. PLoS One 2014;13:47
149. Hasegawa A, Yasuoka J, Ly P, et al. Integrating child health services into malaria control services of village malaria workers in remote Cambodia: service utilization and knowledge of malaria management of caregivers. Malar J 2013;12:292
150. Cox J, Sovannaroth S, Dy Soley L, et al. Novel approaches to risk stratification to support malaria elimination: an example from Cambodia. Malar J 2014;13:371
151. Yasuoka J, Poudel KC, Ly P, et al. Scale-up of community-based malaria control can be achieved without degrading community health workers' service quality: the Village Malaria Worker project in Cambodia. Malar J 2012;11:4
152. White NJ, Pongtavornpinyo W, Maude RJ, et al. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 2009;8:253
153. Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 2008;52(5):1589-96
154. Rottmann M, McNamara C, Yeung BK, et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 2010;329(5996):1175-80
155. Charman SA, Arbe-Barnes S, Bathurst IC, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci USA 2011;108(11):4400-5
156. Burrows JN, Burlot E, Campo B, et al. Antimalarial drug discovery-The path towards eradication. Parasitology 2014; 141(1):128-39
157. Wang X, Dong Y, Wittlin S, et al. Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres. J Med Chem 2013;56(6):2547-55
158. Moehrle JJ, Duparc S, Siethoff C, et al. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol 2013;75(2):524-37
159. Vaidya AB, Morrisey JM, Zhang Z, et al. Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Nat Commun 2014;5:5521
160. Strangio S. Hun Sen's Cambodia. Yale University Press, New Haven, CT, USA; 2014. p. 45
161. Miotto O, Almagro-Garcia J, Manske M, et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet 2013;45(6): 648-55
162. Rathod PK, McErlean T, Lee PC. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 1997;94(17):9389-93